Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of AKB-6548 reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    AKB-6548

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 3Vafseo

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Vafseo

    Vadadustat

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Vafseo

    Japan
    arrow
    AAPS 2024
    Not Confirmed

    Mitsubishi Tanabe

    Vadadustat

    Main Therapeutic Indication : Nephrology

    Currency : USD

    2021 Revenue in Millions : 7

    2020 Revenue in Millions : 0

    Growth (%) : 100

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Vafseo

    Vadadustat

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Vafseo

    Japan
    arrow
    AAPS 2024
    Not Confirmed

    Mitsubishi Tanabe

    Vadadustat

    Main Therapeutic Indication : Nephrology

    Currency : USD

    2022 Revenue in Millions : 15

    2021 Revenue in Millions : 8

    Growth (%) : 79

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Vafseo

    Vadadustat

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Vafseo

    Japan
    arrow
    AAPS 2024
    Not Confirmed

    Mitsubishi Tanabe

    Vadadustat

    Main Therapeutic Indication : Nephrology

    Currency : USD

    2023 Revenue in Millions : 15

    2022 Revenue in Millions : 15

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF